" class="no-js "lang="en-US"> Niels-Henrik von-Holstein-Rathlou - Medtech Alert
Wednesday, September 17, 2025

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
Niels-Henrik von-Holstein-Rathlou

Niels-Henrik von-Holstein-Rathlou

About Niels-Henrik von-Holstein-Rathlou

Related Story

News

 Novo Nordisk Foundation and Broad Institute of MIT and Harvard Launch New Research Center for Genomic Mechanisms of Disease | Pharmtech Focus

Novo Nordisk Foundation and Broad Institute of MIT and Harvard Launch New Research Center for Genomic Mechanisms of Disease

September 16 2021

The Novo Nordisk Foundation and the Broad Institute of MIT and Harvard announced today the launch of the Novo Nordisk Foundation Center for Genomic Mechanisms of Disease, an initiative that will accelerate efforts to mine genetic data […]